HOIST is developing anti-cancer products with novel mechanism-of-action utilizing the MA-T® system. Further, we are pursuing epitranscriptomics drug discovery via a novel target, ALKBH. In addition, we run a drug discovery support business for our clients creating patient derived cells (PDC) / patient derived xenografts (PDX). In pharmaceutical development, HOIST aims to utilize partnerships with pharmaceutical companies (via licensing-out, joint drug discovery etc.). In the drug discovery support business, we tailor PDC/PDX solutions to individual needs of our clients, and contribute to higher success rate of product development.
A startup from UCF’s School of Medicine applying exosome technology to regenerative medicine, drug delivery, non-invasive diagnostics, and medical device development. It aims to improve quality of life through innovative healthcare solutions for intractable diseases.
For the 1.2 million patients with chronic heart failure in Japan, a wristwatch-type wearable device will be used to detect heart murmurs and changes in activity levels specific to heart failure and recommend that patients seek medical attention. After the consultation, doctors will adjust oral medication, ultimately reducing re-hospitalization due to worsening heart failure.
A startup leveraging its proprietary language processing technology, SATOMI®, to support the automatic generation of medical records and referral letters. By streamlining information use in clinical settings, it promotes regional collaboration and medical DX, contributing to the development of a sustainable healthcare system.
Utilizing the unique genome editing technology CRISPR-Cas3, C4U develops industrial applications to combat diseases that currently have no effective treatments.
